A little experimentation, combined with guidance from your provider, can go a long way toward finding what clicks for you
The impact of tirzepatide on clinical kidney outcomes is part of the SURPASS CVOT (T2D patients) and multimorbidity outcomes (people with overweight or obesity without T2D) (91), albeit as secondary endpoints
It focuses on comparison and decision support, then narrows the issue through semaglutide, tirzepatide, cost and coverage, provider access
You may use these files with your own 1-1 clients, as part of group workshops, or as a value-add to a membership program in a locked online portal
We believe you need a structured one
It can be conveniently administered at home without the need for a medical professional, thanks to our easy-to-use method